[唾液生物标志物对口腔癌及潜在恶性疾病的诊断准确性：一项系统评价方案]
[Diagnostic accuracy of salivary biomarkers for oral cancer and potentially malignant disorders: A systematic review protocol].
作者信息
Madera Meisser, Franco Juan Víctor Ariel, Solà Ivan, Bonfill Xavier, Arévalo-Rodriguez Ingrid
机构信息
Departamento de Investigaciones, Facultad de Odontología, Universidad de Cartagena, Cartagena, Colombia; Centro Cochrane Iberoamericano, Instituto de Investigación Biomédica Sant Pau, Barcelona, España. Adress: Zaragocilla Cra. 50 No. 29 11. Cartagena, Colombia. Código postal: 130014. Email:
Cochrane Argentina, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina. ORCID: 0000-0003-0411-899X.
出版信息
Medwave. 2020 Jun 24;20(5):e7938. doi: 10.5867/medwave.2020.05.7938.
INTRODUCTION
Oral cancer has a 5-year survival rate of 50% because diagnosis is commonly performed at an advanced stage of the disease, so new diagnostic tools are needed. Nowadays, there is a vast number of publications suggesting the use of salivary biomarkers for oral cancer and potentially malignant disorders diagnosis, but their diagnostic accuracy is unclear. Thus, the goal of this systematic review is to evaluate the diagnostic accuracy of salivary biomarkers for oral cancer and potentially malignant disorders.
METHODS
This protocol is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). We will include primary studies assessing the diagnostic accuracy of salivary biomarkers for oral cancer and potentially malignant disorders. Studies must report data about sensitivity and specificity; gold standard must be the histopathology diagnosis. We will search MEDLINE, EMBASE, the Cochrane Library, and gray literature. Two authors will independently select the studies and extract the data. The methodology quality of studies will be determined using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2).
EXPECTED RESULTS AND CONCLUSION
Our findings will provide information about the diagnostic accuracy of salivary biomarkers for oral cancer and potentially malignant disorders.
引言
口腔癌的5年生存率为50%，因为诊断通常在疾病的晚期进行，所以需要新的诊断工具。如今，有大量出版物建议使用唾液生物标志物来诊断口腔癌和潜在恶性疾病，但其诊断准确性尚不清楚。因此，本系统评价的目的是评估唾液生物标志物对口腔癌和潜在恶性疾病的诊断准确性。
方法
本方案根据系统评价和Meta分析方案的首选报告项目（PRISMA-P）进行报告。我们将纳入评估唾液生物标志物对口腔癌和潜在恶性疾病诊断准确性的原始研究。研究必须报告敏感性和特异性数据；金标准必须是组织病理学诊断。我们将检索MEDLINE、EMBASE、Cochrane图书馆和灰色文献。两位作者将独立选择研究并提取数据。研究的方法学质量将使用诊断准确性研究质量评估（QUADAS-2）来确定。
预期结果和结论
我们的研究结果将提供有关唾液生物标志物对口腔癌和潜在恶性疾病诊断准确性的信息。
Zotero 插件